<DOC>
	<DOC>NCT00226265</DOC>
	<brief_summary>The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.</brief_summary>
	<brief_title>The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients</brief_title>
	<detailed_description>The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>Cardiac surgery patients who are between the ages of 18 and 100 Are English speaking Able to give consent Undergoing cardiac surgery including (but not limited to): Aortic valve replacement (AVR) Mitral valve replacement (MVR) Tricuspid valve replacement (TVR) Coronary artery bypass graft (CABG). Noncardiac surgery patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cardiac surgery patients</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Recall bias</keyword>
	<keyword>Aortic valve replacement</keyword>
	<keyword>Mitral valve replacement</keyword>
	<keyword>Tricuspid valve replacement</keyword>
	<keyword>Coronary artery bypass graft surgery</keyword>
</DOC>